ATE216590T1 - Arzneimittelformulierungen für il-12 - Google Patents

Arzneimittelformulierungen für il-12

Info

Publication number
ATE216590T1
ATE216590T1 AT96905322T AT96905322T ATE216590T1 AT E216590 T1 ATE216590 T1 AT E216590T1 AT 96905322 T AT96905322 T AT 96905322T AT 96905322 T AT96905322 T AT 96905322T AT E216590 T1 ATE216590 T1 AT E216590T1
Authority
AT
Austria
Prior art keywords
drug formulations
formulations
administration
methods
storage
Prior art date
Application number
AT96905322T
Other languages
English (en)
Inventor
Nicholas W Warne
Thomas J Crowley
Tracy M Smith
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE216590T1 publication Critical patent/ATE216590T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT96905322T 1995-02-06 1996-02-02 Arzneimittelformulierungen für il-12 ATE216590T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38406295A 1995-02-06 1995-02-06
PCT/US1996/001382 WO1996024369A1 (en) 1995-02-06 1996-02-02 Formulations for il-12

Publications (1)

Publication Number Publication Date
ATE216590T1 true ATE216590T1 (de) 2002-05-15

Family

ID=23515877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905322T ATE216590T1 (de) 1995-02-06 1996-02-02 Arzneimittelformulierungen für il-12

Country Status (7)

Country Link
US (1) US5744132A (de)
EP (1) EP0820299B1 (de)
JP (1) JP2000510813A (de)
AT (1) ATE216590T1 (de)
AU (1) AU695129B2 (de)
DE (1) DE69620877T2 (de)
WO (1) WO1996024369A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
PL193286B1 (pl) * 1998-03-26 2007-01-31 Schering Corp Liofilizowany proszek koniugatów glikol polietylenowy - interferon-alfa i zawierające go wyroby
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な６−アミジノ−２−ナフチル４−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
IL147599A0 (en) * 1999-07-15 2002-08-14 Genetics Inst Formulations for il-11
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (de) 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Komplexe aus säugetier-interleukin-12 p40 und interleukin b30, antikörper, verwendung in pharmazeutischen zusammensetzungen
HU0800692D0 (en) * 1999-10-04 2009-01-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1374898B1 (de) * 2001-03-12 2007-06-27 Institute of Gene and Brain Science Verwendung von interleukin-12 zur behandlung von nervenschäden
EP1412384B1 (de) 2001-06-28 2007-12-26 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
DK1441589T3 (da) * 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
EP1599222B1 (de) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
RU2421238C2 (ru) 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
ATE476967T1 (de) 2004-08-12 2010-08-15 Schering Corp Stabile pegylierte interferon-formulierung
ES2395035T3 (es) * 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
PL1817048T3 (pl) 2004-11-12 2014-07-31 Novo Nordisk As Stabilne preparaty peptydów insulinotropowych
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8367054B2 (en) * 2006-11-24 2013-02-05 Cadila Healthcare Limited Formulations of PEG-interferon alpha conjugates
JP2010519220A (ja) * 2007-02-16 2010-06-03 ワイス エルエルシー マンニトール誘導性のタンパク質凝集を抑制するためのスクロースの使用
MX2009008769A (es) * 2007-02-16 2009-08-25 Wyeth Corp Formulaciones de proteina que contienen sorbitol.
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR20100016661A (ko) * 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 대뇌 아밀로이드 혈관병증의 예방 및 치료
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2571516T3 (en) 2010-05-18 2018-02-05 Neumedicines Inc IL-12 FORMULATIONS FOR STIMULATING HEMOPOIES
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
EP2718456B1 (de) 2011-06-13 2019-04-24 Neumedicines, Inc. Linderung von hautverletzungen mittels il-12
EP2736530B1 (de) 2011-07-27 2018-06-06 Neumedicines, Inc Verwendung von il-12 zur erzeugung von endogenem erythropoetin
ES2937409T3 (es) 2011-10-28 2023-03-28 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
US9636381B2 (en) 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
EP2807188B1 (de) 2012-01-27 2019-09-11 Prothena Biosciences Limited Alpha-synuclein erkennende humanisierte antikörper
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
SG11202103192RA (en) * 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
EP4106727A1 (de) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmazeutische formulierungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
JP2893653B2 (ja) * 1988-11-10 1999-05-24 ジェネティックス・インスティテュート・インコーポレイテッド ナチュラルキラー細胞刺激因子
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0433827B1 (de) * 1989-12-22 1998-03-04 F. Hoffmann-La Roche Ag Zytotoxischer Lymphozyten-Reifefaktor
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
AU695129B2 (en) 1998-08-06
JP2000510813A (ja) 2000-08-22
US5744132A (en) 1998-04-28
DE69620877T2 (de) 2002-12-12
MX9705959A (es) 1997-11-29
EP0820299A1 (de) 1998-01-28
WO1996024369A1 (en) 1996-08-15
AU4911996A (en) 1996-08-27
DE69620877D1 (de) 2002-05-29
EP0820299B1 (de) 2002-04-24

Similar Documents

Publication Publication Date Title
DE69620877T2 (de) Arzneimittelformulierungen für il-12
DK0758248T3 (da) Formuleringer til faktor IX
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
SE9201628D0 (sv) Pharmaceutical composition
WO2001005355A3 (en) Formulations for il-11
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
NO990789L (no) Cytotoksisk aminosukker og beslektede sukker-derivater av indolopyrrolokarbazoler
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
IT1270618B (it) Proteine ad attivita' antitumorale
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ATE28188T1 (de) Antikonvulsive mittel.
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
BG104452A (en) New derivatives of the methylenebisphosphonic acid
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli